103 related articles for article (PubMed ID: 14747615)
1. Alterations in vesicular dopamine uptake contribute to tolerance to the neurotoxic effects of methamphetamine.
Johnson-Davis KL; Truong JG; Fleckenstein AE; Wilkins DG
J Pharmacol Exp Ther; 2004 May; 309(2):578-86. PubMed ID: 14747615
[TBL] [Abstract][Full Text] [Related]
2. Methylphenidate alters vesicular monoamine transport and prevents methamphetamine-induced dopaminergic deficits.
Sandoval V; Riddle EL; Hanson GR; Fleckenstein AE
J Pharmacol Exp Ther; 2003 Mar; 304(3):1181-7. PubMed ID: 12604695
[TBL] [Abstract][Full Text] [Related]
3. Age-dependent methamphetamine-induced alterations in vesicular monoamine transporter-2 function: implications for neurotoxicity.
Truong JG; Wilkins DG; Baudys J; Crouch DJ; Johnson-Davis KL; Gibb JW; Hanson GR; Fleckenstein AE
J Pharmacol Exp Ther; 2005 Sep; 314(3):1087-92. PubMed ID: 15901804
[TBL] [Abstract][Full Text] [Related]
4. Lobeline attenuates methamphetamine-induced changes in vesicular monoamine transporter 2 immunoreactivity and monoamine depletions in the striatum.
Eyerman DJ; Yamamoto BK
J Pharmacol Exp Ther; 2005 Jan; 312(1):160-9. PubMed ID: 15331654
[TBL] [Abstract][Full Text] [Related]
5. Bupropion increases striatal vesicular monoamine transport.
Rau KS; Birdsall E; Hanson JE; Johnson-Davis KL; Carroll FI; Wilkins DG; Gibb JW; Hanson GR; Fleckenstein AE
Neuropharmacology; 2005 Nov; 49(6):820-30. PubMed ID: 16005476
[TBL] [Abstract][Full Text] [Related]
6. Attenuated microglial activation mediates tolerance to the neurotoxic effects of methamphetamine.
Thomas DM; Kuhn DM
J Neurochem; 2005 Feb; 92(4):790-7. PubMed ID: 15686480
[TBL] [Abstract][Full Text] [Related]
7. Persistence of tolerance to methamphetamine-induced monoamine deficits.
Danaceau JP; Deering CE; Day JE; Smeal SJ; Johnson-Davis KL; Fleckenstein AE; Wilkins DG
Eur J Pharmacol; 2007 Mar; 559(1):46-54. PubMed ID: 17239369
[TBL] [Abstract][Full Text] [Related]
8. Chronic stress augments the long-term and acute effects of methamphetamine.
Matuszewich L; Yamamoto BK
Neuroscience; 2004; 124(3):637-46. PubMed ID: 14980734
[TBL] [Abstract][Full Text] [Related]
9. Age-dependent effects of methamphetamine on VMAT-2.
Rau KS; Truong JG; Wilkins DG; Fleckenstein AE; Hanson GR
Ann N Y Acad Sci; 2006 Aug; 1074():154-9. PubMed ID: 17105913
[TBL] [Abstract][Full Text] [Related]
10. Methamphetamine-induced alterations in monoamine transport: implications for neurotoxicity, neuroprotection and treatment.
Volz TJ; Fleckenstein AE; Hanson GR
Addiction; 2007 Apr; 102 Suppl 1():44-8. PubMed ID: 17493052
[TBL] [Abstract][Full Text] [Related]
11. Kinetic analysis of developmental changes in vesicular monoamine transporter-2 function.
Volz TJ; Hanson GR; Fleckenstein AE
Synapse; 2006 Nov; 60(6):474-7. PubMed ID: 16897727
[TBL] [Abstract][Full Text] [Related]
12. Interactions of dopamine D1 and D2 receptor antagonists with D-methamphetamine-induced hyperthermia and striatal dopamine and serotonin reductions.
Broening HW; Morford LL; Vorhees CV
Synapse; 2005 May; 56(2):84-93. PubMed ID: 15714503
[TBL] [Abstract][Full Text] [Related]
13. Lobeline inhibits the neurochemical and behavioral effects of amphetamine.
Miller DK; Crooks PA; Teng L; Witkin JM; Munzar P; Goldberg SR; Acri JB; Dwoskin LP
J Pharmacol Exp Ther; 2001 Mar; 296(3):1023-34. PubMed ID: 11181937
[TBL] [Abstract][Full Text] [Related]
14. Long-term changes in dopamine-stimulated gene expression after single-day methamphetamine exposure.
Belcher AM; O'Dell SJ; Marshall JF
Synapse; 2009 May; 63(5):403-12. PubMed ID: 19177510
[TBL] [Abstract][Full Text] [Related]
15. Single or multiple injections of methamphetamine increased dopamine turnover but did not decrease tyrosine hydroxylase levels or cleave caspase-3 in caudate-putamen.
Pereira FC; Lourenço ES; Borges F; Morgadinho T; Ribeiro CF; Macedo TR; Ali SF
Synapse; 2006 Sep; 60(3):185-93. PubMed ID: 16739116
[TBL] [Abstract][Full Text] [Related]
16. Escalating dose pretreatment induces pharmacodynamic and not pharmacokinetic tolerance to a subsequent high-dose methamphetamine binge.
O'Neil ML; Kuczenski R; Segal DS; Cho AK; Lacan G; Melega WP
Synapse; 2006 Nov; 60(6):465-73. PubMed ID: 16897726
[TBL] [Abstract][Full Text] [Related]
17. Dopamine D2 receptor activation increases vesicular dopamine uptake and redistributes vesicular monoamine transporter-2 protein.
Truong JG; Newman AH; Hanson GR; Fleckenstein AE
Eur J Pharmacol; 2004 Nov; 504(1-2):27-32. PubMed ID: 15507217
[TBL] [Abstract][Full Text] [Related]
18. The role of the plasmalemmal dopamine and vesicular monoamine transporters in methamphetamine-induced dopaminergic deficits.
Volz TJ; Hanson GR; Fleckenstein AE
J Neurochem; 2007 May; 101(4):883-8. PubMed ID: 17250674
[TBL] [Abstract][Full Text] [Related]
19. Apomorphine increases vesicular monoamine transporter-2 function: implications for neurodegeneration.
Truong JG; Hanson GR; Fleckenstein AE
Eur J Pharmacol; 2004 May; 492(2-3):143-7. PubMed ID: 15178358
[TBL] [Abstract][Full Text] [Related]
20. Microglial activation precedes dopamine terminal pathology in methamphetamine-induced neurotoxicity.
LaVoie MJ; Card JP; Hastings TG
Exp Neurol; 2004 May; 187(1):47-57. PubMed ID: 15081587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
